These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 27614165)

  • 1. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
    Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
    J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
    Soellradl I; Kehrer H; Cejka D
    Transplant Proc; 2020 Mar; 52(2):657-659. PubMed ID: 32044081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
    Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
    J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
    Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
    Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
    Alhamad T; Venkatachalam K; Linette GP; Brennan DC
    Am J Transplant; 2016 Apr; 16(4):1332-3. PubMed ID: 26752406
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
    Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
    Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in challenging populations.
    Johnson DB; Sullivan RJ; Menzies AM
    Cancer; 2017 Jun; 123(11):1904-1911. PubMed ID: 28241095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
    Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
    Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
    Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD; Kluger H; Callahan MK; Postow MA; Rizvi NA; Lesokhin AM; Segal NH; Ariyan CE; Gordon RA; Reed K; Burke MM; Caldwell A; Kronenberg SA; Agunwamba BU; Zhang X; Lowy I; Inzunza HD; Feely W; Horak CE; Hong Q; Korman AJ; Wigginton JM; Gupta A; Sznol M
    N Engl J Med; 2013 Jul; 369(2):122-33. PubMed ID: 23724867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.